RiverPark Advisors’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-6,100
Closed -$1.02M 72
2018
Q2
$1.02M Sell
6,100
-3,200
-34% -$514K 0.21% 56
2018
Q1
$1.56M Hold
9,300
0.3% 54
2017
Q4
$1.52M Buy
9,300
+2,500
+37% +$449K 0.22% 61
2017
Q3
$1.39M Buy
6,800
+600
+10% +$140K 0.18% 60
2017
Q2
$1.51M Buy
6,200
+400
+7% +$94K 0.17% 62
2017
Q1
$1.39M Sell
5,800
-2,200
-28% -$512K 0.09% 61
2016
Q4
$1.68M Buy
8,000
+2,700
+51% +$559K 0.88% 45
2016
Q3
$1.22M Buy
+5,300
New +$1.3M 0.27% 51

Other funds holding AGN

RiverPark Advisors's AGN Position: Q3 2018 in Review

RiverPark Advisors sold out of Allergan plc (AGN) in Q3 2018, closing a stake of 6,100 shares — an estimated $1.02M sold.

RiverPark Advisors first reported a position in AGN in Q3 2016 and held it in 8 quarters. The position peaked at $1.68M in Q4 2016. 1,067 funds tracked by Wall St. Rank hold AGN as of Q3 2018.

  • RiverPark Advisors reported no remaining Allergan plc position as of Q3 2018 after selling out during the quarter.
  • RiverPark Advisors sold 6,100 Allergan plc shares in Q3 2018, an estimated $1.02M.
  • RiverPark Advisors first reported a position in Allergan plc in Q3 2016 and held it in 8 quarters.
  • RiverPark Advisors's Allergan plc position peaked at $1.68M in Q4 2016.
  • 1,067 funds tracked by Wall St. Rank held Allergan plc as of Q3 2018.

Based on RiverPark Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.